Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial

@article{Ohkusa2010NewlyDA,
  title={Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial},
  author={Toshifumi Ohkusa and Kimitoshi Kato and Shuichi Terao and Toshimi Chiba and Katsuhiro Mabe and Kazunari Murakami and Yuji Mizokami and Toshiro Sugiyama and Akinori Yanaka and Yoshiaki Takeuchi and Shigeru Yamato and Tetsuji Yokoyama and Isao Okayasu and Sumio Watanabe and Hisao Tajiri and Nobuhiro Sato},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105},
  pages={1820-1829}
}
OBJECTIVES:Fusobacterium varium may contribute to ulcerative colitis (UC). We conducted a double-blind placebo-controlled multicenter trial to determine whether antibiotic combination therapy induces and/or maintains remission of active UC.METHODS:Patients with chronic mild-to-severe relapsing UC were randomly assigned to oral amoxicillin 1500 mg/day, tetracycline 1500 mg/day, and metronidazole 750 mg/day, vs. placebo, for 2 weeks, and then followed up. The primary study end point was clinical… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Communicable ulcerative colitis induced by Tbet defi ciency in the innate immune system

WS Garrett, GM Lord, S Punit
Cell • 2007

Meta - analysis : the effi cacy , adverse events , and adherence related to fi rstline antiHelicobacter pylori quadruple therapies

LA Fischbach, S vanZanten, J Dickason
Aliment Pharmacol Th er • 2004

Similar Papers

Loading similar papers…